Progress in the treatment of psoriasis is undeniable. However, not everything Griffiths and colleagues discuss has come to ...

Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias ...

Researchers at the University of Copenhagen have developed an electrospun nanofibre patch for the easier and more effective ...

Psoriasis severity and systemic inflammation linked to cardiovascular disease: insights for better patient care.

Discover how immune checkpoint inhibitors, a revolutionary cancer therapy, increase psoriasis risk. Essential insights for ...

"SEC outperformed placebo by effectively reducing pruritus intensity, restoring clinical normalcy to skin lesions, and ...

The study, published in JAMA Dermatology, revealed that psoriasis severity, measured by the Psoriasis Area and Severity Index ...

From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then to IL-23 inhibitors, biologics have brought new light to the treatment of psoriasis again. In recent years, the exploration of ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...